Earnings Beats and FDA Nods Drive Solid Q2 Execution Across Mid-Cap Tech and Biotech

Cross-sector momentum is accelerating into the second half of 2026, driven by solid Q2 execution, robust margin expansion, and pivotal regulatory milestones. Iovance Biotherapeutics (IOVA.US) led the biotech charge, posting record Q2 revenue of $99.3 million—up a staggering 66% year-over-year—fueled by the rapid commercialization of its Amtagvi therapy. On the clinical front, Replimune Group (REPL.US) is navigating a highly anticipated regulatory window, recently securing a favorable 10-3 FDA advisory committee vote for its oncolytic immunotherapy, effectively setting the stage for a transformative commercial launch.

Hardware and infrastructure operators are equally laser-focused on operational discipline. Alpha and Omega Semiconductor (AOSL.US) delivered an earnings beat for its fiscal Q4 2026, citing resilient demand in AI servers and advanced computing to offset broader semiconductor cyclicality. Meanwhile, Blink Charging (BLNK.US) showcased aggressive cost controls, expanding its Q2 gross margins to 38.9% and slashing adjusted EBITDA losses by 72% to just $2.2 million. Pivoting toward global expansion, ATRenew (RERE.US) rolled out its FoneSquare B2B platform in July, aiming to capture high-margin, cross-border device lifecycle demand.

Traditional mining and specialized healthcare services provided stable anchors amid the growth narrative. Agnico Eagle Mines (AEM.US) generated record quarterly free cash flow on $3.77 billion in Q2 revenue, prompting immediate upward price target revisions from Wall Street analysts. In the services sector, mobile diagnostics provider PDI Health (PDI.US) continues to expand its geographic footprint under institutional demand. Companies navigating quieter operational phases—including Sanmina Corporation (SANM.US), sports apparel maker ANTA (ANTA.US), and ONDG (ONDG.US)—remain focused on underlying macroeconomic conditions and broader consumer sentiment as fiscal 2026 progresses.